EUROPE INJECTABLE DRUG DELIVERY MARKET 2019-2028

MARKET OUTLOOK
Research by Triton shows that the Asia-Pacific injectable drug delivery market would be fast progressing at a CAGR of 9.66% in terms of revenue over the forecast period of 2019-2028.
India, China, Japan, South Korea, Australia & New Zealand, ASEAN countries, and Rest of APAC together from the market in this region.
The market for injectable drug delivery in India is driven primarily by the growth in the prevalence of cardiovascular diseases. According to the journal of the American College of Cardiology published in 2016, CVD is one of the leading causes of death in India. The death rate due to cardiovascular diseases in that year increased by around 34% from 1990. Nanoparticle-based drug delivery is preferred as a therapy option for patients with cardiovascular diseases. This is how the growing prevalence of CVD is increasing the demand for injectable drug delivery technologies in the country. This is fueling the growth of its injectable drug delivery market in the forecasting period.
Furthermore, Pacific Bridge Medical, one of the world’s leading medical companies, states that South Korea’s pharma industry has grown tremendously over the last two decades, ranking at the third position in the overall APAC market. Besides, the country has an efficient healthcare system, which provides high-quality and budget-friendly treatment to its population. These factors are propelling the growth of the Korean injectable drug delivery market in the coming years.
COMPETITIVE OUTLOOK
Some of the companies that have been mentioned in the market report are Terumo Corporation, Teva Pharmaceuticals, Baxter International Inc, Eli Lilly and Company, Novartis AG, Ypsomed Holding AG, Elcam Medical, and Injex.

TABLE OF CONTENTS
1. ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. PORTER’S FIVE FORCES MODEL
2.2.1. THREAT OF NEW ENTRANT
2.2.2. THREAT OF SUBSTITUTE
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. INTENSITY OF COMPETITIVE RIVALRY
2.3. KEY INSIGHT
2.4. KEY BUYING CRITERIA
2.5. MARKET ATTRACTIVENESS INDEX
2.6. MARKET DRIVERS
2.6.1. INCREASING GERIATRIC POPULATION
2.6.2. TECHNOLOGICAL ADVANCEMENT
2.6.3. GROWING OCCURRENCE OF AUTOIMMUNE DISEASES
2.7. MARKET RESTRAINTS
2.7.1. HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS
2.8. MARKET OPPORTUNITIES
2.8.1. DEVELOPMENT OF BETTER INJECTABLE SYSTEMS
2.8.2. INCREASE IN HEALTHCARE EXPENDITURE
2.9. MARKET CHALLENGES
2.9.1. DEVELOPMENTS IN ALTERNATE DRUG DELIVERY SYSTEMS
2.9.2. STRINGENT REGULATIONS
3. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE
3.1. PEN INJECTOR
3.2. AUTO?INJECTOR
3.3. NEEDLE-FREE INJECTOR
3.4. PREFILLED SYRINGE
4. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION
4.1. SUBCUTANEOUS
4.2. INTRAMUSCULAR
4.3. INTRAVENOUS (IV)
4.4. OTHER ROUTE OF ADMINISTRATION
5. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER
5.1. CLINICS/ PHYSICIAN OFFICES
5.2. AMBULATORY CARE
5.3. HOSPITAL
5.4. HOME-BASED
5.5. OTHER END-USERS
6. INJECTABLE DRUG DELIVERY MARKET – ASIA-PACIFIC
6.1. COUNTRY ANALYSIS
6.1.1. JAPAN
6.1.2. CHINA
6.1.3. AUSTRALIA & NEW ZEALAND
6.1.4. INDIA
6.1.5. SOUTH KOREA
6.1.6. ASEAN COUNTRIES
6.1.7. REST OF ASIA-PACIFIC
7. COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC
7.2. BECTON DICKINSON AND COMPANY (BD)
7.3. ELCAM MEDICAL
7.4. ELI LILLY AND COMPANY
7.5. GERRESHEIMER
7.6. INJEX
7.7. NOVARTIS AG
7.8. NOVO NORDISK A/S
7.9. PFIZER INC
7.10. SANOFI SA
7.11. SCHOTT AG
7.12. TERUMO CORPORATION
7.13. TEVA PHARMACEUTICALS
7.14. WEST PHARMACEUTICALS
7.15. YPSOMED HOLDING AG
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS


LIST OF TABLES
TABLE 1 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)
TABLE 2 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 3 DIFFERENT TYPES OF INSULIN PEN INJECTORS
TABLE 4 MARKETED NEEDLE-FREE INJECTORS PRODUCTS
TABLE 5 LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE
TABLE 6 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 7 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 8 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)

LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 2 KEY BUYING IMPACT ANALYSIS
FIGURE 3 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)
FIGURE 4 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY AUTO?INJECTOR, 2019-2028 ($ MILLION)
FIGURE 5 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 6 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)
FIGURE 7 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)
FIGURE 8 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR, 2019-2028 ($ MILLION)
FIGURE 9 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS, 2019-2028 ($ MILLION)
FIGURE 10 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
FIGURE 11 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/ PHYSICIAN OFFICES, 2019-2028 ($ MILLION)
FIGURE 12 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)
FIGURE 13 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)
FIGURE 14 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)
FIGURE 15 ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)
FIGURE 16 JAPAN INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 17 CHINA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 18 AUSTRALIA & NEW ZEALAND INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 19 INDIA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 20 SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 21 ASEAN COUNTRIES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 22 REST OF ASIA-PACIFIC INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)